Human immunoglobulin treatments, delivered either intravenously (IVIG) or subcutaneously (SCIG), play a vital role in managing primary antibody deficiencies (PADs) by preventing bacterial infections.
The Company’s novel approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and pathways and associated anti-tumor and anti-viral immune responses will ...